{"id":"leflunomide-sulfasalazine-hydroxychloroquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Retinal toxicity (hydroxychloroquine)"}]},"_chembl":{"chemblId":"CHEMBL1535","moleculeType":"Small molecule","molecularWeight":"335.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leflunomide inhibits dihydroorotate dehydrogenase to reduce pyrimidine synthesis in T and B cells. Sulfasalazine acts as an anti-inflammatory and immunosuppressant through multiple mechanisms including NF-κB inhibition. Hydroxychloroquine accumulates in lysosomes to modulate immune responses and reduce inflammatory cytokine production. Together, these agents provide complementary immunosuppressive effects.","oneSentence":"This triple-drug combination suppresses immune system activity through multiple pathways to reduce inflammation and autoimmune disease progression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:27.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT06915701","phase":"PHASE2, PHASE3","title":"\"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis\"","status":"RECRUITING","sponsor":"University of Guadalajara","startDate":"2026-02-06","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT06640309","phase":"PHASE2","title":"The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2023-12-02","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05447520","phase":"PHASE2","title":"Montelukast Use in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Noha Mansour","startDate":"2021-12-15","conditions":"Rheumatoid Arthritis","enrollment":92},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT04066803","phase":"PHASE4","title":"Optimal MTX Dose With Folic Acid Randomized Case-control Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-01","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT03863405","phase":"PHASE2","title":"Metformin Use in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-01-09","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01709578","phase":"PHASE3","title":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":546},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT02057250","phase":"PHASE3","title":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"RA","enrollment":217},{"nctId":"NCT01313208","phase":"PHASE4","title":"Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT01256736","phase":"PHASE3","title":"To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":89},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00422227","phase":"PHASE4","title":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arava®","Azulfidine®","Plaquenil®"],"phase":"phase_3","status":"active","brandName":"Leflunomide-Sulfasalazine-Hydroxychloroquine","genericName":"Leflunomide-Sulfasalazine-Hydroxychloroquine","companyName":"University of Nebraska","companyId":"university-of-nebraska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination suppresses immune system activity through multiple pathways to reduce inflammation and autoimmune disease progression. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}